Rimegepant. calcitonin gene-related peptide (CGRP) receptor antagonist, treatment of migraine
Rimegepant is an oral calcitonin gene-related peptide
(CGRP) receptor antagonist and is currently under
development by Biohaven Pharmaceuticals for the acute
and preventive treatment of migraine. Among patients
with acute migraine, significant clinical efficacy has been
reported with a rimegepant single dose. The completed
pivotal phase II and III trials showed a beneficial action of
rimegepant in terms of pain freedom, pain relief, release
of migraine symptoms and lifestyle recovery. Moreover,
adverse events were mild or moderate and did not cause
trial discontinuation. Several clinical trials are currently
ongoing to evaluate long-term safety and efficacy profiles
in patients with migraine and refractory trigeminal
neuralgia. Drug–drug interactions potentially affecting
rimegepant pharmacokinetics should be assessed in future
clinical trials.